RMD Stock Recent News
RMD LATEST HEADLINES
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, RJF and KBR are some stocks that hold promise.
The SPDR S&P 500 ETF Trust ended 2024 on a sour note, losing 2.41% in December and finishing the year up 24.89%. The Top 15 dividend growth stocks for January 2025 offer an average dividend yield of 1.21% and appear to be about 27% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.33% compound annual growth rate.
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. RACE, VERX, RMD and HUBB are some stocks that hold promise.
ResMed introduces digital and personalized solutions designed to improve sleep health.
NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in New York City. ResMed also announced its five-year revenue and earnings growth outlook, reflecting ResMed's plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. Driven by the new strategy, ResMed expects to help more than 500 million people worldwide achieve their full health potential in 2030.